It takes a team to remove large, aggressive tumors

July 26, 2011

(Medical Xpress) -- No cancer surgery is easy, but the two operations David Bieszke underwent at Loyola University Hospital to remove an aggressive, 10-inch tumor were especially challenging.

The extended from his navel to his . It choked a major blood vessel and invaded smaller blood vessels to both kidneys.

It would take two surgeries, each lasting 6 hours, to remove the tumor. There was a significant risk that Mr. Bieszke could lose one or both kidneys. He might have to go on a heart-lung bypass machine during . There was even a chance he could bleed to death.

"I was really scared," said Mr. Bieszke, 47, who lives in Geneva, Ill.

Three days before the first surgery, David and Jennifer Bieszke got married. They had been together for 18 years, and David had asked Jennifer more than once to get married. As he faced the difficult and risky surgery, she finally said yes.

"I realized that if I lost him, I would always regret that we hadn't gotten married," Jennifer Bieszke said. "That piece of paper had become very important to me."

The two-part operation was a multidisciplinary effort that required exhaustive planning and close teamwork among four top surgeons, an anesthesiologist, the head nurse and the rest of the operating team.

"Everyone worked together so well," said surgical oncologist Dr. Margo Shoup, who coordinated the team. "It was like a beautiful sympathy."

The team was able to remove the entire tumor and save one of Mr. Bieszke's kidneys. Four weeks after his second surgery, Mr. Bieszke returned to work as an auto mechanic. He feels better now than he has in a long time.

Prior to surgery, Mr. Bieszke suffered pain near his stomach for more than a year. He took ibuprofen three or four times a day, lost his appetite and suffered .

He finally was diagnosed on April 3. An oncologist at a community hospital referred Mr. Bieszke to Dr. Shoup, because it would require an academic medical center such as Loyola to perform the highly specialized, multidisciplinary surgery.

The cancer, relatively rare, is known as vena cava sarcoma. Doctors believe it originated in the vena cava, the largest vein in the body. By the time Mr. Bieszke was diagnosed, the tumor had completely blocked the vena cava, forcing the body to grow alternative blood vessels.

The first surgery was performed April 29. Surgeons successfully removed the left side of the tumor, but were unable to save the left kidney.

The second surgery was performed June 13. Dr. Shoup worked closely with vascular surgeon Dr. Ross Milner, kidney transplant surgeon Dr. Amy Lu, cardiothoracic surgeon Dr. Robert Love, Dr. Jeffrey Hartwig and head nurse Jill Anderson.

Dr. Lu and Dr. Milner removed cancerous parts of blood vessels to the right kidney and then reconstructed the . There was a chance Dr. Lu would have to remove the kidney and, in effect, transplant it back in a different location. Fortunately, that wasn't necessary. Mr. Bieszke's right kidney stayed in place and is working normally.

Dr. Love was available in the event the tumor reached the heart and Mr. Bieszke would have to be put on a heart-lung bypass machine during the surgery. Perfusionists also were set up and ready to go on bypass at any time. Fortunately, this wasn't necessary, either.

Dr. Milner removed about 5 inches of the vena cava and Dr. Shoup removed the rest of the tumor. Dr. Hartwig infused blood to make up for blood loss and kept Mr. Biezke's vital signs stable throughout the surgery. Ms. Anderson was instrumental in making the surgery proceed without a hitch.

Today, Mr. Bieszke appears to be cancer free. But he will need regular CT scans because there's a chance the cancer could come back.

He and his wife are confident it won't.

"And even if it does, we will have Dr. Shoup," Mrs. Biezke said. "We couldn't ask for more than that."

Related Stories

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.